{'fraction_non_alphanumeric': 0.022031823745410038, 'fraction_numerical': 0.0012239902080783353, 'mean_word_length': 6.175438596491228, 'pattern_counts': {'":': 0, '<': 0, '<?xml version=': 0, '>': 0, 'https://': 0, 'lorem ipsum': 0, 'www.': 0, 'xml': 0}, 'pii_count': 0, 'substrings_counts': 0, 'word_list_counts': {'cursed_substrings.json': 0, 'profanity_word_list.json': 0, 'sexual_word_list.json': 0, 'zh_pornsignals.json': 0}}
Pancreatic Cancer: Adjuvant Chemo‐RT, Still Controversial, Shows Evidence of Increasing Survival

O RLANDO, FL—While still a topic of controversy, the use of adjuvant chemoradiation in pancreatic patients after resection is further supported by new research presented here at the Gastrointestinal Cancers Symposium, which is cosponsored by the American Society of Clinical Oncology, the American Gastroenterology Association Institute, the American Society for Therapeutic Radiology and Oncology, and the Society of Surgical Oncology. In a retrospective review, Johns Hopkins Hospital and Mayo Clinic researchers found that overall survival rates were higher among patients who received adjuvant radiation plus fluorouracil (5-FU)-based chemotherapy than among patients who did not receive the chemoradiation regimen.